Latest filing published 25 Aug 2026 for Amneal Pharmaceuticals, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Andrew S. Boyer (senior executive) discloses dealings in Amneal Pharmaceuticals, Inc. to SEC (Form 4). The record holds 73 filings, for trades running from 4 May 2018 to 21 August 2026.
Market trades split into 2 purchases (€332k) and 6 sales (€4.1M). Taken together, the sales exceed the purchases by €3.8M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 32 share grants and 32 option exercises.
On 25 August 2026 came the latest disclosure, a transaction in Amneal Pharmaceuticals, Inc. The clock since the last published purchase (7 August 2019) now reads 2,634 days. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
22 of 22 declarations